This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Pemfexy — Description, Dosage, Side Effects | PillsCard
Rx
Pemfexy
500 mg, Proszek do sporządzania koncentratu roztworu do infuzji
INN: Pemetrexedum
Data updated: 2026-04-13
Available in:
🇨🇿🇩🇪🇬🇧🇪🇸🇵🇱🇵🇹🇸🇰
Form
Proszek do sporządzania koncentratu roztworu do infuzji
Dosage
500 mg
Route
dożylna
Storage
Storage and Handling Store Pemetrexed Injection at controlled refrigerated temperature, 2°C to 8°C (36°F to 46°F). Pemetrexed Injection is a hazardous drug. Follow applicable special handling and disposal procedures. [see References (15) ]
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
About This Product
Manufacturer
Eli Lilly Nederland B.V. (Francja)
Composition
Pemetrexedum 500 mg
ATC Code
L01BA04
Source
URPL
11 DESCRIPTION Pemetrexed is a folate analog metabolic inhibitor. Pemetrexed diacid, the drug substance, has the chemical name N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glumatic acid. The molecular formula is C 20 H 21 N 5 O 6 and the molecular weight is 427.41. The structural formula is as follows: PEMFEXY (pemetrexed injection) for intravenous use is a sterile, clear, colorless to yellow or green-yellow solution . Each mL contains: 25 mg pemetrexed diacid, 260 mg propylene glycol, up to 16.5-19.9 mg tromethamine, and water for injection. Additional tromethamine not exceeding 19.9 mg/mL and/or hydrochloric acid may be added for pH adjustment. Chemical Structure
⚠️ Warnings
1. Use aseptic technique during the reconstitution and further dilution of pemetrexed for intravenous infusion administration.
2. Calculate the dose and the number of ALIMTA vials needed. Each vial contains an excess of pemetrexed to facilitate delivery of label amount.
3.
ALIMTA 100 mg
Reconstitute 100‑mg vials with 4.2 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
ALIMTA 500 mg
Reconstitute 500‑mg vials with 20 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, resulting in a solution containing 25 mg/ml pemetrexed.
Gently swirl each vial until the powder is completely dissolved. The resulting solution is clear and ranges in colour from colourless to yellow or green-yellow without adversely affecting product quality. The pH of the reconstituted solution is between 6.6 and 7.8.
Further dilution is required
.
4. The appropriate volume of reconstituted pemetrexed solution must be further diluted to 100 ml with sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, and administered as an intravenous infusion over 10 minutes.
5. Pemetrexed infusion solutions prepared as directed above are compatible with polyvinyl chloride and polyolefin lined administration sets and infusion bags.
6. Parenteral medicinal products must be inspected visually for particulate matter and discolouration prior to administration. If particulate matter is observed, do not administer.
7. Pemetrexed solutions are for single use only. Any unused medicinal product or waste material must be disposed of in accordance with local requirements.
Preparation and administration precautions
As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of pemetrexed infusion solutions. The use of gloves is recommended. If a pemetrexed solution contacts the skin, wash the skin immediately and thoroughly with soap and water. If pemetrexed solutions contact the mucous membranes, flush thoroughly with water. Pemetrexed is not a vesicant. There is not a specific antidote for extravasation of pemetrexed. There have been few reported cases of pemetrexed extravasation, which were not assessed as serious by the investigator. Extravasation should be managed by local standard practice as with other non‑vesicants.